Journal article
ML290 is a biased allosteric agonist at the relaxin receptor RXFP1
Martina Kocan, Mohsin Sarwar, Sheng Y Ang, Jingbo Xiao, Juan J Marugan, Mohammed A Hossain, Chao Wang, Dana S Hutchinson, Chrishan S Samuel, Alexander I Agoulnik, Ross AD Bathgate, Roger J Summers
Scientific Reports | NATURE PUBLISHING GROUP | Published : 2017
Grants
Awarded by National Health and Medical Research Council of Australia
Awarded by National Health and Medical Research Council Program
Awarded by Australian Research Council
Awarded by National Cancer Institute
Funding Acknowledgements
We thank Sharon Layfield and Tania Ferraro for technical assistance, Dr Melanie White (Australian Institute for Regenerative Medicine, Monash University) for the pENTR L1-R5 Ef1 alpha construct and Prof. Alon Chen (Weizmann Institute of Science, Israel) for the gift of pMDL, pRev and pVSVG plasmids. Research at the Florey was supported by National Health and Medical Research Council of Australia project grants 628427 and 1043750 (RADB) and by the Victorian Government Operational Infrastructure Support Program. CSS 1041766 and RADB 1042650 are NHMRC Senior Research Fellows and DSH 545952 is an NHMRC Career Development Fellow. Research at Drug Discovery Biology, Monash Institute of Pharmaceutical Science was supported by National Health and Medical Research Council Program Grant 1055134 (RJS) and by Australian Research Council Linkage Grant LP110100288 (RJS, RADB, CSS) and Industry Partner Corthera Inc. Research at Florida International University was supported by National Cancer Institute grant U01CA177711 (AIA). (San Mateo, CA) who also supplied H2 relaxin.